ArticleFrontiers in oncology2026
PPIB and its role in prostate cancer: associations with transcriptomic and splicing alterations.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While peptidyl-prolyl cis-trans isomerase B (PPIB) has been implicated in tumorigenesis and RNA metabolism, its specific function in prostate cancer is poorly understood. Methods: PPIB expression was assessed in clinical prostate adenocarcinoma samples and the TCGA-PRAD cohort. In PC-3 cells, stable PPIB knockdown was achieved via lentiviral shRNA. Subsequent Results: TCGA-PRAD analysis showed significantly higher PPIB mRNA expression in tumors. In the paired IHC cohort, an exploratory ROI-level comparison showed higher PPIB H-scores in tumor regions than in adjacent non-tumor regions (P < 0.05). Because multiple ROIs were obtained from the same patients, patient-level inference was based on ROI-averaged paired values; the mean tumor H-score was higher, but the paired difference was not statistically significant. PPIB knockdown inhibited cell proliferation, migration, invasion, and xenograft tumor growth. A modest increase in apoptotic cells was observed after PPIB depletion. Transcriptomic analysis revealed 570 differentially expressed genes and 873 altered splicing events, with enriched pathways involving DNA repair, the cell cycle, and amino acid metabolism. Integrating DEG and ASE data identified 22 overlapping genes, including the metabolic regulators PHGDH and SHMT2. Re-expression of shRNA-resistant PPIB significantly reversed the reductions in migration and invasion caused by PPIB knockdown. Conclusions: PPIB promotes prostate cancer progression and is associated with broad transcriptional and alternative splicing alterations. These results indicate a role for PPIB in prostate cancer progression and establish a foundation for investigating its post-transcriptional functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.